Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban

BACKGROUND: In nonvalvular atrial fibrillation (NVAF), rivaroxaban is used to prevent stroke and systemic embolism. OBJECTIVE: To evaluate major bleeding (MB) in NVAF patients treated with rivaroxaban in a real‐world clinical setting. METHODS: From January 1, 2013, to March 31, 2014, US Department o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamayo, Sally, Frank Peacock, W., Patel, Manesh, Sicignano, Nicholas, Hopf, Kathleen P., Fields, Larry E., Sarich, Troy, Wu, Shujian, Yannicelli, Daniel, Yuan, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2015
Materias:
Quality and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685471/
https://www.ncbi.nlm.nih.gov/pubmed/25588595
http://dx.doi.org/10.1002/clc.22373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685471/
https://www.ncbi.nlm.nih.gov/pubmed/25588595
http://dx.doi.org/10.1002/clc.22373

Ejemplares similares